Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury
Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou
Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou
View: Text | PDF
Research Article Immunology Nephrology

Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury

  • Text
  • PDF
Abstract

Macrophages, endowed with remarkable phenotypic plasticity, are essential for orchestrating injury responses and regulating iron homeostasis. Given the central role of ferritin heavy chain (FtH) as a molecular rheostat linking iron sequestration to redox-dependent signaling, we examined how myeloid FtH governs renal iron trafficking and ensuing oxidative stress pathways during acute kidney injury (AKI). Transcriptome analysis revealed coupling of FtH deficiency in monocytes and macrophages with activation of ferroptosis, a regulated cell death associated with iron accumulation. Moreover, myeloid FtH deletion worsened AKI, increasing leukocyte infiltration and iron deposition, together with ferroptosis-associated gene induction, oxidative stress, and lipid peroxidation. Notably, α-synuclein (SNCA), an iron-binding protein and the main pathological driver of Parkinson’s disease, was robustly induced both by FtH deficiency and following AKI. Mechanistic studies showed that monomeric SNCA exhibits ferrireductase activity, amplifying redox cycling and promoting ferroptotic cell death. Furthermore, SNCA expression was elevated in kidney pathologies characterized by leukocyte expansion in both mouse models and human cohorts, suggesting that inflammatory microenvironments promote SNCA accumulation and redox imbalance. These findings define a macrophage FtH/SNCA regulatory axis as a key driver of ferroptosis in AKI, implicating SNCA as a pathological nexus between iron dyshomeostasis and inflammatory kidney injury.

Authors

Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou

×

Figure 6

Monomeric SNCA’s ferrireductase activity drives oxidative stress, a hallmark of ferroptosis.

Options: View larger image (or click on image) Download as PowerPoint
Monomeric SNCA’s ferrireductase activity drives oxidative stress, a hall...
(A) Representative Western blot showing dose-dependent uptake of recombinant monomeric SNCA by BMDMs after 16 hours of incubation. Recombinant SNCA was used as a positive control. (B) For uptake assays, BMDMs were treated with A488-labeled recombinant SNCA, and the A488 signal was monitored using live-cell imaging. The green signal indicates successful internalization of the recombinant monomeric SNCA. Scale bars: 100 μm. (C) Representative Western blot showing HNE and ACSL4 expression levels in BMDMs treated with vehicle or SNCA. (D and E) Densitometric quantification of HNE (D) and ACSL4 (E) expression (n = 6 for all treatment groups). (F and G) mRNA expression levels of Slc7a11 (F) and Slc40a1 (G) in BMDMs treated with vehicle or SNCA (n = 6 for all treatment groups). (H) Representative flow cytometry plot showing ROS detection using DCFDA in BMDMs treated with vehicle or monomeric SNCA. (I) Representative histogram of DCFDA fluorescence intensity. (J) Quantification of ROS-positive cells following SNCA treatment (n = 6 for all treatment groups). (K) Representative flow cytometry plot showing lipid peroxidation levels measured using BODIPY 581/591 in BMDMs treated with vehicle or monomeric SNCA. (L) Representative histogram of BODIPY fluorescence intensity. (M) Quantification of BODIPY-positive cells (n = 6 for all treatment groups). (N) Representative images demonstrating intracellular ROS using DCFDA in BMDMs treated with increasing concentrations of SNCA. Scale bars: 100 μm. (O) Representative Western blot demonstrates HNE expression in BMDMs treated with vehicle, monomeric SNCA, boiled monomeric SNCA, proteinase K–treated monomeric SNCA, or aggregated SNCA (fibrils) for 16 hours. (P) Densitometric quantification of HNE expression, normalized to GAPDH (n = 6 for all treatment groups). NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts